Increased Treatment-Related Toxicity Subsequent to an Anti–PD-1 Agent
Department of Medical Oncology (GU/Melanoma), Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON M5G 2M9, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2015, 22(4), 320-322; https://doi.org/10.3747/co.22.2418
Submission received: 3 May 2015
/
Revised: 6 June 2015
/
Accepted: 9 July 2015
/
Published: 1 August 2015
Excerpt
Note: In lieu of an abstract, this is an excerpt from the first page.
The approval of ipilimumab [...]
Share and Cite
MDPI and ACS Style
Khoja, L.; Butler, M.O.; Chappell, M.A.; Hogg, D.; Joshua, A.M. Increased Treatment-Related Toxicity Subsequent to an Anti–PD-1 Agent. Curr. Oncol. 2015, 22, 320-322. https://doi.org/10.3747/co.22.2418
AMA Style
Khoja L, Butler MO, Chappell MA, Hogg D, Joshua AM. Increased Treatment-Related Toxicity Subsequent to an Anti–PD-1 Agent. Current Oncology. 2015; 22(4):320-322. https://doi.org/10.3747/co.22.2418
Chicago/Turabian StyleKhoja, Leila, Marcus Ortho Butler, Mary Anne Chappell, David Hogg, and Anthony M. Joshua. 2015. "Increased Treatment-Related Toxicity Subsequent to an Anti–PD-1 Agent" Current Oncology 22, no. 4: 320-322. https://doi.org/10.3747/co.22.2418
